XLO Stock Analysis: Buy, Sell, or Hold?
XLO - Xilio Therapeutics, Inc. Common Stock
$9.23
0.00 (0.00%)
â˛
5d:
+0.65%
30d:
+11.07%
90d:
+7.64%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When XLO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: XLO is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: XLO is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: XLO is currently trading at $9.23, which is considered slightly high relative to its 30-day fair value range of $8.77 to $9.33. From a valuation perspective, the stock is trading at a discount (Forward PE: -4.1) compared to its historical average (23.0). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, XLO is in a strong uptrend. Immediate support is located at $8.68, while resistance sits at $9.90.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $20.00 (+116.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, XLO is in a strong uptrend. Immediate support is located at $8.68, while resistance sits at $9.90.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $20.00 (+116.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$8.77 -
$9.33
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
70.0%
All Signals
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 116.7% below Wall St target ($20.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 51/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$8.77 -
$9.33
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$8.68
Resistance Level
$9.90
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.14
Wall Street Target
$20.00
(+116.7%)
Revenue Growth (YoY)
131.2%
Profit Margin
-34.1%
PE vs Historical
-4.1 vs 23.0
CHEAP
Share & Embed Analysis
Last updated: August 23, 2026 8:43 PM ET
Data refreshes hourly during market hours. Next update: 9:43 PM
Data refreshes hourly during market hours. Next update: 9:43 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XLO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
29 analysts |
$91 | 42 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 66 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 35 SELL |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$102 | 50 HOLD |